15 Stocks That Will Go to The Moon According to Analysts

3. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Average Upside Potential: 83.48%

Number of Hedge Fund Holders: 50

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a global biotechnology company that strives to create breakthrough therapies to cater to genetic diseases. The firm’s primary focus is on Duchenne muscular dystrophy, limb-girdle muscular dystrophies, and Charcot-Marie-Tooth disease.

Sarepta is leading a revolution in precision genetic medicine. The company has the privilege of having leadership positions in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. With more than 40 therapies in various stages of development, the company remains at the forefront of precision genetic medicine.

Recently, the leader in precision genetic medicine for rare diseases reported positive topline results from Part 2 of the EMBARK study, showing disease stabilization and sustained benefits in ambulatory individuals having Duchenne Muscular Dystrophy following treatment with ELEVIDYS. In the UAE, US, Qatar, Kuwait, Bahrain, and Oman, ELEVIDYS is approved for people with Duchenne aged four and above despite their ambulatory status.